DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Deregulation of miRNAs Contributes to Development and Progression of Prostate Cancer
Final rept. 15 Aug 2009-14 Aug 2012
CALIFORNIA UNIV DAVIS
Pagination or Media Count:
In the 3rd year of this grant, we further explored the role miR-125b plays in CaP pathogenesis and found that miR-125b targets the tumor suppressive gene p14ARF. We also performed animal studies to validate our previous finding that miR-125b contributes to tumorigenesis of CaP. Furthermore, we observed that targeting miR-125b using anti-miR-125b inhibits growth of CaP tumors and sensitizes CaP cells to the anti-CaP drug Taxol. In addition, we examined 133 clinical prostate samples, and found that an increased miR-125b level is common in clinical CaP samples, which may be associated with CaP progression. These findings, together with those in the first and second year, support our hypothesis that miR-125b acts as an oncogene, contributing to the development and progression of CaP. Therefore, targeting miR-125b may represent a new strategy for improved CaP treatment.
APPROVED FOR PUBLIC RELEASE